Radioactive drug targets hard-to-treat neuroendocrine tumors in early trial
NCT ID NCT07661420
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1 trial tests a radioactive drug called 211At-MABG in 16 adults with advanced neuroendocrine cancers, including pheochromocytoma and paraganglioma. The drug delivers radiation directly to cancer cells that show up on a special scan. The main goal is to see if the treatment schedule is feasible and safe, not yet to cure the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 211At-MABG (a radioactive drug that targets cancer cells)
- What this could lead to
- If it works, this could lead to a new treatment option for people with advanced neuroendocrine cancers that have stopped responding to other therapies.
- What could go wrong
- This is a very early phase 1 trial with only 16 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects from radiation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIAL CARCINOID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pennsylvania - Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can a black seed extract boost immunotherapy against a rare cancer?
- Can a radioactive 'Smart Bomb' take down resistant childhood cancers?
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- Can a Three-Drug cocktail shrink Hard-to-Treat neuroendocrine tumors?